673A preferentially depletes CD133+ ovarian CSCs, inhibits ovarian tumor initiation in vitro and in vivo, synergizes with chemotherapy against both breast and ovarian cancer cells, and increased tumor eradication in chemotherapy-resistant human-patient-derived xenograft models 29. Here, PROM1 is linked to neoplasm.